Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Issue 3 (23rd February 2022)

• Record Type: Journal Article
• Authors: Aussedat, Guillaume; Maucort-Boulch, Delphine; Rey, Philippe; Safar, Violaine; Karlin, Lionel; Elsensohn, Mad Helenie; Bachy, Emmanuel; Lebras, Laure; Favier, Bertrand; Vantard, Nicolas; Ghergus, Dana; Golfier, Camille; Sesques, Pierre; Lazareth, Anne; Lequeu, Hélène; Ferrant, Emmanuelle; Salles, Gilles; Nicolas-Virelizier, Emmanuelle; Ghesquieres, Hervé
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 3(2022)
• Page Start: 599
• Page End: 607
• Publication Date: 2022-02-23
• Subjects: Diffuse large B-cell lymphoma -- relapse -- refractory -- transplantation-ineligible -- salvage therapy -- rituximab–ifosfamide–etoposide; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1998483
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m 2 ) in combination with etoposide (300 mg/m 2 ) and ifosfamide (1500 mg/m 2 ) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64–92). The median number of previous line was 1 (range 1–8). Patients received a median of six cycles (1–12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3–4 neutropenia (19%), 7 a grade 3–4 thrombocytopenia (10%) without grade 3–4 non-hematological toxicity. With a median follow up of 7.8 months, the median progression-free survival, overall survival, and duration of response were 4.4 months, 9.4 months, and 12 months, respectively. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT.